Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.
The Pain & Fatigue Study Center at Mount Sinai Beth Israel in New York has been awarded a United States Army Medical Research grant to conduct a study into the treatment of veterans of the 1990-1991 Gulf War who have Gulf War Illness using electroCore’s non-invasive vagus nerve stimulation (nVNS)
Research presented at the Academy of Managed Care Pharmacy (AMCP) Nexus in early October in Washington, DC, showed that 60 percent of adult patients who were diagnosed with primary headache had one or more comorbidities which raised the average annual cost of their healthcare to over $20,000.
Basking Ridge, New Jersey: Frank Amato, previously Chief Operating Officer, has been appointed Chief Executive Officer of electroCore, the Merck-backed world leader in non-invasive vagus nerve stimulation (nVNS) therapy. This change is part of a management-proposed development plan, unanimously
The results of two studies, presented at the American Headache Society (AHS) Science Meeting last weekend in San Diego, show that using electroCore’s non-invasive vagus nerve stimulation (nVNS) therapy, gammaCore®, is effective at preventing both cluster headache and menstrual migraine.
Recent clinical and preclinical results using electroCore’s non-invasive vagus nerve stimulation (nVNS, gammaCore®) therapy in the treatment and prevention of primary headache are the subject of seven presentations at the American Headache Society (AHS) Science Meeting being held at San Diego next
BASKING RIDGE, N.J: A paper in the Journal of Headache and Pain reports that non-invasive stimulation of the vagus nerve (nVNS) is a cost effective therapy for cluster headache. These findings were based on reductions in medication use and improvements in quality of life.
electroCore welcomes the recent NIHR technology alert on gammaCore, which profiles the CE-marked device’s role in helping patients in the UK manage long-term neurological conditions such as migraine and medically unexplained symptoms. The alert, which is designed to notify clinicians and those
BASKING RIDGE, N.J: The UK’s National Institute of Health and Care Excellence (NICE) has published guidance that electroCore’s non-invasive vagus nerve stimulation treatment (gammaCore) for the prevention and acute treatment of migraine and cluster headache is safe and can now be used in the NHS.
A study published in the Journal of Headache and Pain, carried out by Dr. Thomas Kinfe of the University of Bonn, found that twice daily stimulation of the vagus nerve with the hand-held gammaCore nVNS device reduced the number of headache days per month from 14.7 to 8.9 (p
Basking Ridge, New Jersey: ElectroCore’s non-invasive vagus nerve stimulation device, gammaCore, will be launched across Germany by Desitin for the treatment of migraine and cluster headache. The agreement with Desitin who are specialists in the CNS area took effect on January 1st, 2016. Desitin,